In the context of all three conditions—multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody-associated disease—integrated biomarker platforms that synthesize fluid-based, imaging, and immunological indicators constitute the frontier of biomarker research. The gene discussed is OMG; the disease is multiple sclerosis.